New Targets in the Management of Prostate Cancer

Hematology/Oncology Clinics of North America

Volumn 20, Issue 4, 2006, Pages 985-999

  Heath, Elisabeth I ^a   Carducci, Michael A ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AP 23573; ATRASENTAN; BORTEZOMIB; BOSENTAN; CANERTINIB; CETUXIMAB; DOCETAXEL; ERLOTINIB; ESTRAMUSTINE; EVEROLIMUS; GEFITINIB; IMATINIB; L 778123; LAPATINIB; LEFLUNOMIDE; LENALIDOMIDE; LONAFARNIB; MATUZUMAB; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PANITUMUMAB; PELITINIB; PERTUZUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; SEMAXANIB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; ZD 4054; ZOLEDRONIC ACID;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CARDIOTOXICITY; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA BINDING; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFICACY; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GENE CONTROL; GENE OVEREXPRESSION; GRAFT RECIPIENT; HUMAN; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY METASTASIS; LUNG CANCER; MORNING SICKNESS; NEUROTOXICITY; OVERALL SURVIVAL; PANCREAS ISLET CELL CARCINOMA; PREGNANT WOMAN; PRIORITY JOURNAL; PROSTATE CANCER; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TARGET CELL DESTRUCTION; TERATOGENICITY;

ANGIOGENESIS INHIBITORS; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; GROWTH INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33745986714     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.05.001     Document Type: Review

References (79)

1. Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 170 6 Pt 2 (2003) S77-S83 [discussion: S]
2. Perdona S., Autorino R., De Placido S., et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6 5 (2005) 295-300
3. Le Page C., Koumakpayi I.H., Lessard L., et al. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65 2 (2005) 130-140
4. El Sheikh S.S., Domin J., Abel P., et al. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6 6 (2004) 846-853
5. Bonaccorsi L., Marchiani S., Muratori M., et al. Signaling mechanisms that mediate invasion in prostate cancer cells. Ann N Y Acad Sci 1028 (2004) 283-288
6. Slovin S.F., Kelly W.K., Cohen R., et al. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): results of a phase Ib/IIa study. [abstract]. Proc Am Soc Clin Oncol 16 311a (1997) abstract 1108
7. Foon K.A., Yang X.D., Weiner L.M., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58 3 (2004) 984-990
8. Yang X.-D., Wang P., Fredlin P., et al. ABX-EGF a fully human anti-EGF receptor monoclonal antibody: inhibition of prostate cancer in vitro and in vivo. [abstract]. Proc Am Soc Clin Oncol 21 (2002) abstract 2454
9. Figlin R., Belldegrun A.S., Crawford J., et al. ABX-EGF a fully human antiepidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results. [abstract]. Proc Am Soc Clin Oncol 21 10a (2002) abstract 35
10. Vanhoefer U., Tewes M., Rojo F., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 1 (2004) 175-184
11. Ziada A., Barqawi A., Glode L.M., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60 4 (2004) 332-337
12. Morris M.J., Reuter V.E., Kelly W.K., et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 94 4 (2002) 980-986
13. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
14. George D.J., Halabi S., Shepard T.F., et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7 7 (2001) 1932-1936
15. Franklin M.C., Carey K.D., Vajdos F.F., et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 4 (2004) 317-328
16. Agus D.B., Gordon M.S., Taylor C., et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23 11 (2005) 2534-2543
17. Sgambato A., Camerini A., Faraglia B., et al. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 201 1 (2004) 97-105
18. Bonaccorsi L., Marchiani S., Muratori M., et al. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 130 10 (2004) 604-614
19. Sirotnak F.M., She Y., Lee F., et al. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 8 12 (2002) 3870-3876
20. Canil C.M., Moore M.J., Winquist E., et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23 3 (2005) 455-460
21. Schröder F.H., Wildhagen M.F., and Erasmus M.C. ZD1839 (gefitinib) and hormone resistant (HR) prostate cancer-final results of a double blind randomized placebo-controlled phase II study. [abstract]. Proc Am Soc Clin Oncol 22 14S (2004) abstract 4698
22. Trump D.L., Wilding G., Miller K., et al. Pilot trials of ZD1839 (Iressa), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. J Urol 169 4 Suppl (2003) 244
23. Formento P., Hannoun-Levi J.M., Fischel J.L., et al. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 40 18 (2004) 2837-2844
24. Huang S., Armstrong E.A., Benavente S., et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 15 (2004) 5355-5362
25. Matar P., Rojo F., Cassia R., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10 19 (2004) 6487-6501
26. Hoekstra R., Dumez H., Eskens F.A., et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 11 19 Pt 1 (2005) 6908-6915
27. Devi G.R., Beer T.M., Corless C.L., et al. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 11 10 (2005) 3930-3938
28. Nunes M., Shi C., and Greenberger L.M. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 3 1 (2004) 21-27
29. Nemunaitis J., Eiseman I., Cunningham C., et al. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 11 10 (2005) 3846-3853
30. Chott A., Sun Z., Morganstern D., et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155 4 (1999) 1271-1279
31. Kubler H.R., van Randenborgh H., Treiber U., et al. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 63 4 (2005) 385-394
32. George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol 532 (2003) 141-151
33. Rao K., Goodin S., Levitt M.J., et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62 2 (2005) 115-122
34. Tiffany N.M., Ryan C.W., Garzotto M., et al. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 174 3 (2005) 888-892
35. Kim S.J., Uehara H., Yazici S., et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 65 9 (2005) 3707-3715
36. Ko Y.J., Small E.J., Kabbinavar F., et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 7 4 (2001) 800-805
37. Rademaker-Lakhai J.M., Horenblas S., Meinhardt W., et al. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 11 5 (2005) 1854-1862
38. Rosenbaum E., and Carducci M.A. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Expert Opin Pharmacother 4 6 (2003) 875-887
39. Carducci M.A., Nelson J.B., Padley R.J., et al. The endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a multinational, randomized, double-blind, placebo-controlled trial. [abstract]. Proc Am Soc Clin Oncol 20 (2001) abstract 64
40. Carducci M.A., Nelson J.B., Saad F., et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. [abstract]. J Clin Oncol 22 14S (2004) abstract 4508
41. Yuyama H., Noguchi Y., Fujimori A., et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol 498 1-3 (2004) 171-177
42. Dreicer R., Curtis N., Morris C., et al. ZD4054 specifically inhibits endothelin A receptor-mediated effects, but not endothelin B receptor-mediated effects. [abstract]. ASCO Prostate Cancer Symposium (2005) abstract 237
43. Mazieres J., Pradines A., and Favre G. Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett 206 2 (2004) 159-167
44. Haas N., Peereboom D., Ranganathan S., et al. Phase II trial of R115777, an inhibitor of farnesyltransferase, in patients with hormone refractory prostate cancer. [abstract]. Proc Am Soc Clin Oncol 21 (2002) abstract 721
45. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
46. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 5 (2005) 965-972
47. Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65 7 (2005) 2825-2831
48. Shamash J., Dancey G., Barlow C., et al. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 92 1 (2005) 36-40
49. Grunwald V., DeGraffenried L., Russel D., et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62 21 (2002) 6141-6145
50. Thomas G., Speicher L., Reiter R., et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiences. [abstract]. AACR-NCI-EORTC International Conference (2005) abstract C131
51. Solit D.B., Scher H.I., and Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30 5 (2003) 709-716
52. Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8 5 (2002) 962-966
53. Heath E.I., Gaskins M., Pitot H.C., et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4 2 (2005) 138-141
54. Williams S., Pettaway C., Song R., et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2 9 (2003) 835-843
55. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 11 (2004) 2108-2121
56. Messersmith W.A., Baker S.D., Lassiter L., et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12 4 (2006) 1270-1275
57. Carducci M.A., Gilbert J., Bowling M.K., et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7 10 (2001) 3047-3055
58. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 10 Pt 1 (2003) 3578-3588
59. Pili R., Kruszewski M.P., Hager B.W., et al. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61 4 (2001) 1477-1485
60. Qian D.Z., Ren M., Wei Y., et al. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate 64 1 (2005) 20-28
61. Butler L.M., Agus D.B., Scher H.I., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 18 (2000) 5165-5170
62. Strohmeyer D., Strauss F., Rossing C., et al. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 24 3a (2004) 1797-1804
63. Duque J.L., Loughlin K.R., Adam R.M., et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 3 (1999) 523-527
64. Retter A.S., Figg W.D., and Dahut W.L. The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer 2 3 (2003) 153-159
65. Picus J., Halabi S., Rini B., et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HPRC): initial results of CALGB 90006. [abstract]. Proc Am Soc Clin Oncol 22 (2003) abstract 1578
66. Beebe J.S., Jani J.P., Knauth E., et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63 21 (2003) 7301-7309
67. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 10 (2005) 4389-4400
68. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 18 (2005) 4162-4171
69. Salesi N., Carlini P., Ruggeri E.M., et al. Prostate cancer: the role of hormonal therapy. J Exp Clin Cancer Res 24 2 (2005) 175-180
70. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 6 (2004) 1025-1033
71. Figg W.D., Dahut W., Duray P., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 7 (2001) 1888-1893
72. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 13 (2004) 2532-2539
73. Frank R.C., Coscia A., Versea N., et al. Low dose docetaxel, estramustine, and thalidomide followed by maintenance thalidomide for the treatment of hormone refractory prostate cancer (HPRC): a phase II community based trial. [abstract]. J Clin Oncol 22 14S (2004) abstract 4681
74. Lilly M., Rowsell E.H., Gurrola R., et al. Phase I trial of sargramostim and thalidomide for treatment of hormone-refractory prostate cancer. [abstract]. J Clin Oncol 22 14S (2004) abstract 4690
75. Tohnya T.M., Ng S.S., Dahut W.L., et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer 2 4 (2004) 241-243
76. Sison B., Bond T., Amato R.J., et al. Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HPRCa). J Clin Oncol 22 14S (2004) abstract 4701
77. Rustin G.J., Galbraith S.M., Anderson H., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21 15 (2003) 2815-2822
78. Evelhoch J.L., LoRusso P.M., He Z., et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10 11 (2004) 3650-3657
79. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10 2 (2004) 415-427